Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 31, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 2, 2026
10% ownerIndirect holdingOther
Context
Classification
other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002074003-26-000008
Filed / recorded
Apr 2, 2026, 11:34 PM UTC
Added to OQRO
Oct 8, 2026, 2:32 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Vivos Therapeutics, Inc.
Issuer CIK
1716166
Ticker
VVOS
Reporting person
Skaff Michael C
Relationship
10% owner
Security
Series A Common Stock Warrant
Table
Derivative (Table II)
Transaction date
Mar 31, 2026
Transaction code
P
Shares / units
1,783,582
Price per share
$1.34
Acquired / disposed
Acquired (A)
Shares owned after
1,783,582
Ownership form
Indirect — By V-CO Investors 3 LLC
Amendment
No
Footnotes from the filing
Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.